Search

Displaying results 4071 - 4080 of 10000 in total
  1. Drug

    Glymidine

    go.drugbank.com/drugs/DB01382
    Approved

    It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. … This increase in intracellular calcium ion concentration induces the secretion of insulin.

    Categories: Drugs Used in Diabetes
  2. Drug

    Clostridium tetani

    go.drugbank.com/drugs/DB09876
    ApprovedInvestigational

    Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, Boostrix Polio - Injektionssuspension in einer Fertigspritze
  3. Drug

    Cefixime

    go.drugbank.com/drugs/DB00671
    ApprovedInvestigational

    [A232920, A232925, A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation semisynthetic cephalosporin. … [A263031] Cefixime was first approved in the United States in 1986.[L49293]

    Products: CEFIXIMA MK 20MG/ML, CEFIXIMA MK 400 MG CAPSULAS
  4. Drug

    Bird pepper

    go.drugbank.com/drugs/DB14262
    Approved

    Bird pepper is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Rice bran

    go.drugbank.com/drugs/DB14361
    Approved

    Rice bran is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  7. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic … [L40026] It received subsequent approval for the same indications in Canada in May 2022.

  8. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  9. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens. … Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.

  10. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.